Protein Signature: Discriminating Common Adenocarcinomas

  • Cancer management stems from initial classification of the patient’s tumor.
  • It is often difficult to identify the tissue site-of-origin of a metastatic cancer when no primary tumor has been identified, and few markers have been identified that allow such classification.
  • Scientists at Moffitt Cancer Center have developed a protein-based classification system that discriminates six common types of adenocarcinoma.

TECHNOLOGY

  • The classifier is based on global protein approach using two=dimensional gels for fractionation, enabling a thorough identification of reliable markers by mass spectrometry.
  • Tumor samples were 77 human tumors from primary sites, improving the accuracy of the signature.
  • Six common tumors were studied: ovary, breast, colon, kidney, lung and stomach.
  • 173 proteins in the signature were found unique to individual tumor types, representing candidate tumor biomarkers for each type.
  • The proteomics signature can be applied using other protein fractionation and detection methods.

PUBLICATION/PATENT

  • G. Bloom et al. (2006) Int. J. Cancer 120:769-775.
  • Patent application pending.

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

05A014